This event will offer a week of biotech, pharma and finance, including several very interesting on demand sessions. The digital event, October 25-28, will include one-to-one meetings, company presentations, company
Nordic Life Science
NOT A SUBSCRIBER? SIGN UP TODAY AND GET THE FULL LIFE SCIENCE PICTURE
ONLY 13 €/MONTH
NLS News
During the last day of SALSS (the Swedish-American Life Science Summit) 2021 in Stockholm, the winner of the Rising Star Award was announced. And the lucky winner was… EpiEndo Pharmaceuticals.
Oncopeptides has announced that the company has decided to withdraw Pepaxto (INN melphalan flufenamide) from the market in the US, following the phase 3 OCEAN study, which showed an overall
Ultimovacs has announced that its universal cancer vaccine, UV1, in combination with checkpoint inhibitors has received Fast Track designation from the U.S. FDA in the treatment of unresectable or metastatic
As the coronavirus swept across the globe over the past year, science has been in the spotlight, sometimes embraced, sometimes vilified. The lackluster response by former US President Donald J.
BioLamina with partners in the innovation milieu IndiCell receive funding to establish and propel individualized cell therapy treatments in Sweden. The funded project focuses on an autologous therapy model, in
Flerie Invest led a syndicate of investors in the 52 million USD acquisition of Charles River Laboratories Inc’s DNA and protein manufacturing subsidiary Cobra Biologics Matfors AB, including its 7,000
Genetic Analysis has been awarded an important patent by the China National Intellectual Property Agency (CNIPA). The patent entitled “A method for determining gastrointestinal tract dysbiosis” covers the company’s algorithm
This event will offer a week of biotech, pharma and finance, including several very interesting on demand sessions. The digital event, October 25-28, will include one-to-one meetings, company presentations, company
Xbrane Biopharma has been granted two new patents by the Swedish patent and Registration Office (PRV). The patents relate to novel methods of using signal peptides to enhance the production
Salipro Biotech enters into a collaboration and license agreement with AbCellera for access to the Salipro platform for antibody discovery against GPCRs, ion channels, and transporters. The collaboration enables AbCellera
CombiGene and Spark Therapeutics have announced the signing of an exclusive collaboration and licensing agreement for CombiGene’s CG01 project, a gene therapy which aims to treat drug resistant focal epilepsy.
The Cell and Molecular Imaging (CMI) platform makes the visualization of biological systems, from the molecular to the tissue level possible. Cryo-EM enables the reconstruction of near-atomic structures of molecular
The project aims to ensure that even more research results are converted into new therapies or products that can be rapidly disseminated in the healthcare system to benefit patients, employees
The COVID-19 pandemic
The Nordic life science industry has not only survived, but managed to grow and develop during the pandemic. The past 1.5 years have also brought valuable lessons, including the importance
Antibodies in the airways quickly wane after SARS-CoV-2 infection, but vaccination results in a strong increase in antibody levels, especially after two doses, according to a new study from Karolinska
Funded by the National SciLifeLab-KAW COVID-19 Research Program, SciLifeLab researchers from Uppsala University, KTH and Karolinska Institutet have, under the umbrella of the COMMUNITY study, investigated if existing T-cell tests
New results from the TACKLE Phase III COVID-19 treatment trial showed that AZD7442, a long acting antibody (LAAB) combination, achieved a statistically significant reduction in severe COVID-19 or death compared
Researchers at Karolinska Institutet have identified metabolic processes that SARS-CoV-2 uses to attack lung tissue. The results, which are published in Molecular & Cellular Proteomics, could be used to treat
The Nobel Prize
The Nobel Assembly at Karolinska Institutet has today decided to award the 2021 Nobel Prize in Physiology or Medicine jointly to David Julius and Ardem Patapoutian for their discoveries of
One of the receptors discovered by the Nobel Laureates in Medicine is the TRPV1 receptor, which is used by PILA as the leading principle for a novel treatment of diabetes.
The Royal Swedish Academy of Sciences has decided to award the Nobel Prize in Chemistry 2021 to Benjamin List and David W.C. MacMillan, for the development of a precise new
Drug and device development
Updated results from the Phase III trial showed that Imfinzi (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall
Positive results from the HIMALAYA Phase III trial showed a single, high priming dose of tremelimumab added to Imfinzi (durvalumab) demonstrated a statistically significant and clinically meaningful overall survival (OS)
Elicera Therapeutics has presented preclinical proof-of-concept data for its iTANK-platform at the European Society of Gene & Cell Therapy Virtual Congress 2021. Elicera’s technology platform – iTANK (immunoTherapies Activated with
Ultimovacs has announced continuing positive topline results in its ongoing US-based Phase I clinical trial evaluating the company’s universal cancer vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab as
RhoVac has received and validated results from its 3-year follow-up of the patients who took part in its phase I/II study that was concluded in 2018. The top-line results shows
Profile
Being a scientist or an entrepreneur is hard enough. Doing both at the same time sounds like an Olympic sport. Swedish scientist and “serial entrepreneur” Dr. Mathias Uhlén, PhD., professor
In a new job
The pandemic has led to several changes in our working lives, including new digital tools, new kinds of offices and more work-life balance. But it has also meant loss of
Already making a mark as director of the Center for Regional Development, the Capital Region of Denmark, Diana Arsovic Nielsen has taken on a new role as the CEO of
Swedish pharmaceutical company LIDDS has appointed Nina Herne as its new CEO. LIDDS has developed a drug delivery technology, NanoZolid, which provides a controlled and sustained release of active drug
Careers
Nordic Life Science had a chat with last year’s winner of the award Female Leader Engineer, Katarina Atteryd, about the award’s impact on her career and her thoughts on leadership,
Read the latest issue of our magazine!
No 04 2021 // Real-World Evidence has taken a leap forward during the pandemic. Read more about the potential of RWE in drug development, and how we can better enable Nordic health data to be transformative and a frontrunner in this field.
In this issue we have also chosen to turn the spotlight on our successful Nordic profiles abroad. They all provide valuable insights from the global life science industry and give perspectives on the Nordic one.
Last but not least, a very hot topic in the spotlight in this issue is the quest to find and secure talent. We take a closer look on how to keep up with the demand and with whom the responsibility rests to solve the skills supply challenge.
Venture Capital
Nordic Life Science asked Fredrik Dahl, co-founder at Colibri Ventures, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges Nordic life science
Nordic Life Science asked Claus Andersson, General Manager at Sunstone Life Science Venture, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges
Nordic Life Science asked Inka Mero, Founder and Managing Partner at Voima Ventures, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges
“Start by asking what the problem is that you are trying to solve and develop the technology, team, and plan to solve that problem – not what you can do with the technology.” – Fredrik Dahl, Colibri Ventures
Upcoming events
This event will offer a week of biotech, pharma and finance. The digital event will include one-to-one meetings, company presentations, company showcase and interesting keynotes and panels. Global health: Partnering
Outsourcing in Clinical Trials & Clinical Trial Supply Nordics – This event gathers the pharmaceutical, biotechnology, and medical device communities to discuss strategies for operational success in clinical trials. With
MEDICA and COMPAMED will start up again as in-person events. MEDICA 2021, the world’s no. 1 medical trade fair, and COMPAMED 2021, the international main event for medical technology suppliers
The latest research news from the Nordic region
Science Article
One of the receptors discovered by the Nobel Laureates in Medicine is the TRPV1 receptor, which is used by PILA as the leading principle for a novel treatment of diabetes.
AlzeCure Pharma is developing a novel clinical drug candidate for peripheral neuropathic pain, which is based on the seminal discoveries of TRPV1 by Professor Julius, and for which he is
The Royal Swedish Academy of Sciences has decided to award the Nobel Prize in Chemistry 2021 to Benjamin List and David W.C. MacMillan, for the development of a precise new
Throughout the years, Nordic Life Science has interviewed many Nobel Laureates, and among them a few Nordic ones. Arvid Carlsson, Professor of Pharmacology at Sahlgrenska Academy, University of Gothenburg, won
Since 2008 Nordic Life Science has dedicated one of our issues every year to the Nobel Prize. These issues have included exclusive interviews with the Laureates, in-depth articles about the
The Lasker Foundation has announced the winners of its 2021 Lasker Awards. Dieter Oesterhelt (Max Planck Institute of Biochemistry), Peter Hegemann (Humboldt University of Berlin) and Karl Deisseroth (Stanford University)
Nordic Life Science
The latest clinical trials
Positive results from the HIMALAYA Phase III trial showed a single, high priming dose of tremelimumab added to Imfinzi (durvalumab) demonstrated a statistically significant and clinically meaningful overall survival (OS)
Ultimovacs has announced continuing positive topline results in its ongoing US-based Phase I clinical trial evaluating the company’s universal cancer vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab as
RhoVac has received and validated results from its 3-year follow-up of the patients who took part in its phase I/II study that was concluded in 2018. The top-line results shows
Ultimovacs has started dosing of the second cohort in the Phase I TENDU trial, evaluating the company’s Tetanus-Epitope Targeting (TET)-platform. The TENDU clinical trial, conducted at the Oslo University Hospital,
Positive results from the PROpel Phase III trial showed that AstraZeneca and MSD’s Lynparza (olaparib) in combination with abiraterone demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free
The Nordic life science industry has not only survived, but managed to grow and develop during the pandemic. The past 1.5 years have also brought valuable lessons, including the importance
SynAct Pharma completes patient recruitment to the Phase 2a BEGIN study of AP1189 in early severe Rheumatoid Arthritis. With all patients included into the study, dosing will be concluded in
RhoVac’s clinical phase IIb study of lead drug candidate RV001 in prostate cancer, BRaVac, is deemed fully recruited and no additional patients will be screened after this week. Top-line results
Updated results from the Phase III trial showed that Imfinzi (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall
Sign up to our newsletter